Medpace (MEDP) Revenue & Revenue Breakdown
Medpace Revenue Highlights
Latest Revenue (Y)
$2.11B
Latest Revenue (Q)
$659.90M
Main Segment (Y)
Oncology
Medpace Revenue by Period
Medpace Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $2.11B | 11.84% |
| 2023-12-31 | $1.89B | 29.17% |
| 2022-12-31 | $1.46B | 27.80% |
| 2021-12-31 | $1.14B | 23.38% |
| 2020-12-31 | $925.92M | 7.54% |
| 2019-12-31 | $860.97M | 22.19% |
| 2018-12-31 | $704.59M | 61.55% |
| 2017-12-31 | $436.15M | 3.46% |
| 2016-12-31 | $421.58M | 17.41% |
| 2015-12-31 | $359.06M | 23.80% |
| 2014-12-31 | $290.04M | 6.28% |
| 2013-12-31 | $272.89M | - |
Medpace generated $2.11B in revenue during NA 2024, up 11.84% compared to the previous quarter, and up 244.96% compared to the same period a year ago.
Medpace Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $659.90M | 9.38% |
| 2025-06-30 | $603.31M | 8.01% |
| 2025-03-31 | $558.57M | 4.10% |
| 2024-12-31 | $536.59M | 0.61% |
| 2024-09-30 | $533.32M | 0.99% |
| 2024-06-30 | $528.10M | 3.34% |
| 2024-03-31 | $511.04M | 2.54% |
| 2023-12-31 | $498.40M | 1.20% |
| 2023-09-30 | $492.50M | 6.86% |
| 2023-06-30 | $460.87M | 6.17% |
| 2023-03-31 | $434.07M | 10.14% |
| 2022-12-31 | $394.10M | 2.70% |
| 2022-09-30 | $383.74M | 9.26% |
| 2022-06-30 | $351.21M | 6.12% |
| 2022-03-31 | $330.95M | 7.26% |
| 2021-12-31 | $308.55M | 4.39% |
| 2021-09-30 | $295.57M | 6.21% |
| 2021-06-30 | $278.29M | 7.05% |
| 2021-03-31 | $259.96M | 0.11% |
| 2020-12-31 | $259.68M | 12.72% |
| 2020-09-30 | $230.37M | 12.38% |
| 2020-06-30 | $205.00M | -11.21% |
| 2020-03-31 | $230.88M | 0.43% |
| 2019-12-31 | $229.89M | 6.31% |
| 2019-09-30 | $216.24M | 1.00% |
| 2019-06-30 | $214.10M | 6.66% |
| 2019-03-31 | $200.74M | 4.49% |
| 2018-12-31 | $192.12M | 7.18% |
| 2018-09-30 | $179.25M | 5.35% |
| 2018-06-30 | $170.14M | 4.33% |
| 2018-03-31 | $163.08M | 44.72% |
| 2017-12-31 | $112.68M | 1.84% |
| 2017-09-30 | $110.64M | 4.17% |
| 2017-06-30 | $106.22M | -0.37% |
| 2017-03-31 | $106.61M | -1.51% |
| 2016-12-31 | $108.24M | 0.41% |
| 2016-09-30 | $107.80M | 1.74% |
| 2016-06-30 | $105.95M | 6.39% |
| 2016-03-31 | $99.59M | 3.69% |
| 2015-12-31 | $96.04M | 4.24% |
| 2015-09-30 | $92.13M | 4.87% |
| 2015-06-30 | $87.85M | 5.81% |
| 2015-03-31 | $83.03M | 6.55% |
| 2014-03-31 | $77.93M | - |
Medpace generated $659.90M in revenue during Q3 2025, up 9.38% compared to the previous quarter, and up 124.96% compared to the same period a year ago.
Medpace Revenue Breakdown
Medpace Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Central Nervous System | $181.98M | $157.94M | $121.55M | $65.39M | - |
| Metabolic | $457.54M | $244.68M | $159.90M | $138.65M | - |
| Cardiology | $230.45M | $174.63M | $119.69M | $91.26M | - |
| Antiviral And Anti Infective | $156.46M | $118.03M | $110.98M | $86.39M | - |
| Oncology | $651.24M | $467.80M | $362.85M | $256.77M | - |
| Other | $431.38M | $296.91M | $267.42M | $222.51M | - |
| Revenue Net | - | $1.46B | $34.50M | $15.90M | $18.90M |
| Reimbursed Out Of Pocket Revenue | - | - | - | - | - |
| Direct Revenue | - | - | - | - | - |
Latest
Medpace's latest annual revenue breakdown by segment (product or service), as of Dec 24: Oncology (30.88%), Metabolic (21.69%), Other (20.45%), Cardiology (10.93%), Central Nervous System (8.63%), and Antiviral And Anti Infective (7.42%).
Quarterly Revenue by Product
| Product/Service | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Central Nervous System | $65.63M | $61.13M | $54.90M | $49.22M | $42.10M | $46.52M | $44.14M | $43.99M | $37.73M | $38.70M | $37.13M | $43.42M | $38.91M | $38.49M | $35.33M | $32.85M | $28.55M | $24.81M | $21.75M | - |
| Other | $106.40M | $118.06M | $95.84M | $103.18M | $107.37M | $112.43M | $108.40M | $106.16M | $101.06M | $87.10M | $80.17M | $72.77M | $73.56M | $70.42M | $70.27M | $64.09M | $64.12M | $68.94M | $55.54M | - |
| Oncology | $192.63M | $188.56M | $170.48M | $168.17M | $164.92M | $162.95M | $155.20M | $149.33M | $147.09M | $141.95M | $124.21M | $122.83M | $115.54M | $105.21M | $95.74M | $94.72M | $93.25M | $79.14M | $68.63M | - |
| Metabolic | $199.26M | $147.87M | $148.01M | $122.87M | $124.73M | $106.30M | $103.64M | $103.12M | $87.86M | $86.84M | $77.49M | $63.48M | $55.60M | $48.12M | $47.13M | $42.13M | $38.14M | $32.49M | $29.62M | - |
| Cardiology | $59.47M | $58.58M | $58.28M | $58.30M | $55.81M | $60.70M | $55.64M | $44.36M | $51.13M | $46.62M | $45.41M | $49.80M | $42.03M | $37.40M | $33.15M | $34.74M | $28.04M | $23.76M | $27.59M | - |
| Antiviral And Anti Infective | $36.52M | $29.11M | $31.06M | $34.84M | $38.38M | $39.20M | $44.03M | $45.55M | $36.01M | $32.87M | $29.69M | $31.45M | $25.58M | $31.32M | $26.93M | $27.03M | $26.19M | $30.82M | $27.24M | - |
| Revenue Net | - | - | - | - | - | - | - | $492.50M | $460.87M | $434.07M | $394.10M | $383.74M | $17.20M | $13.30K | $10.60M | $8.70M | $9.90M | $5.30M | $4.30M | $3.40M |
Latest
Medpace's latest quarterly revenue breakdown by segment (product or service), as of Sep 25: Metabolic (30.19%), Oncology (29.19%), Other (16.12%), Central Nervous System (9.94%), Cardiology (9.01%), and Antiviral And Anti Infective (5.53%).
Medpace Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CNC | Centene | $163.07B | $49.69B |
| THC | Tenet Healthcare | $20.66B | $5.29B |
| DGX | Quest Diagnostics | $9.87B | $2.82B |
| ICLR | ICON Public | $8.12B | $2.09B |
| SNN | Smith & Nephew | $5.55B | $2.79B |
| ILMN | Illumina | $4.37B | $1.08B |
| HOLX | Hologic | $4.10B | - |
| WAT | Waters | $2.96B | $799.89M |
| WST | West Pharmaceutical Services | $2.89B | $804.70M |
| MEDP | Medpace | $2.11B | $659.90M |
| TEM | Tempus AI | $531.82M | $334.21M |